rosiglitazone has been researched along with cholecalciferol in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gege, C; Hoffmann, T; Schlüter, T | 1 |
| Bayliffe, AI; Lamb, JR; Thompson, PW; Warren, AP | 1 |
| Afzal, R; Bosch, J; Dagenais, G; Diaz, R; Gerstein, H; Holman, R; Probstfield, J; Punthakee, Z; Ramachandran, A; Riddle, M; Rydén, LE; Yusuf, S; Zinman, B | 1 |
| Al-Daghri, NM; Al-Othman, A; Al-Saleh, Y; Alkharfy, KM; Alokail, MS; Chrousos, GP; Kumar, S; Moharram, O; Sabico, SB | 1 |
2 trial(s) available for rosiglitazone and cholecalciferol
| Article | Year |
|---|---|
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholecalciferol; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Neoplasms; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2012 |
Vitamin D supplementation in patients with diabetes mellitus type 2 on different therapeutic regimens: a one-year prospective study.
Topics: Administration, Oral; Adult; Biomarkers; Blood Glucose; Case-Control Studies; Cholecalciferol; Diabetes Mellitus, Type 2; Dietary Supplements; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Rosiglitazone; Saudi Arabia; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Vitamin D; Young Adult | 2013 |
3 other study(ies) available for rosiglitazone and cholecalciferol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
Topics: Benzeneacetamides; Drug Inverse Agonism; Fluorescence Resonance Energy Transfer; Humans; Ligands; Nuclear Receptor Subfamily 1, Group F, Member 2; Nuclear Receptor Subfamily 1, Group F, Member 3; Protein Binding; Th17 Cells; Thiazoles; Tretinoin | 2014 |
Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells.
Topics: CD4-Positive T-Lymphocytes; Cells, Cultured; Cholecalciferol; Dendritic Cells; Dose-Response Relationship, Drug; Drug Synergism; Humans; Interleukin-10; PPAR gamma; Promoter Regions, Genetic; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2007 |